EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Acquired Autoimmune Factor XIII Deficiency as a Novel Immune‐Related Adverse Event of Combined Ipilimumab and Nivolumab Therapy for Renal Cell Carcinoma: A Case Report

Shigeyasu Tetsushi iD, Koura Mikifumi, Ootsubo Satoshi, Hasegawa Shuji, Tatsugami Katsunori

IJU Case Reports · 2026-07 · 9 (4)

DOI: 10.1002/iju5.70207 ↗

Kurz gefasst

Fallbericht in der Zeitschrift IJU Case Reports, online erschienen am 08.07.2026. Verfasst von Shigeyasu Tetsushi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Kitakyushu Shiritsu Iryo Center Kitakyushu Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Combination therapy with immune checkpoint inhibitors (ICIs) has become the standard pharmacological treatment for renal cell carcinoma; however, careful attention must be paid to immune‐related adverse events (irAEs). We report a rare case of acquired autoimmune factor XIII deficiency following ipilimumab plus nivolumab therapy. Case Presentation A 75‐year‐old woman who had previously undergone nephrectomy for left renal cell carcinoma developed pancreatic and pulmonary metastases and was started on combination immunotherapy. Six months after treatment initiation, she presented with bleeding symptoms. Laboratory testing revealed anti‐factor XIII autoantibodies, confirming a diagnosis of acquired autoimmune factor XIII deficiency.

Conclusion

To our knowledge, few reports have described this condition as an irAE. Nonetheless, other irAE‐related acquired coagulation factor deficiencies—such as factor V deficiency and acquired hemophilia A—have been reported. These precedents suggest a high likelihood that the current case represents a novel manifestation of irAE.

Schlagwörter

Stichwörter der Autor:innen

acquired autoimmune factor XIII deficiencyimmune checkpoint inhibitors (ICIs)immune‐related adverse events (irAEs)ipilimumabnivolumabrenal cell carcinoma

Autor:innen und Institutionen

  • Kitakyushu Shiritsu Iryo Center Kitakyushu Japan.

ORCID-Profile: Shigeyasu Tetsushi

Zitieren

APA

Tetsushi, S., Mikifumi, K., Satoshi, O., Shuji, H., & Katsunori, T. (2026). Acquired Autoimmune Factor XIII Deficiency as a Novel Immune‐Related Adverse Event of Combined Ipilimumab and Nivolumab Therapy for Renal Cell Carcinoma: A Case Report. IJU Case Reports, 9(4). https://doi.org/10.1002/iju5.70207

Vancouver

Tetsushi S, Mikifumi K, Satoshi O, Shuji H, Katsunori T. Acquired Autoimmune Factor XIII Deficiency as a Novel Immune‐Related Adverse Event of Combined Ipilimumab and Nivolumab Therapy for Renal Cell Carcinoma: A Case Report. IJU Case Reports. 2026;9(4). doi:10.1002/iju5.70207

BibTeX
@article{Tetsushi2026,
  author = {Tetsushi, Shigeyasu and Mikifumi, Koura and Satoshi, Ootsubo and Shuji, Hasegawa and Katsunori, Tatsugami},
  title = {Acquired Autoimmune Factor XIII Deficiency as a Novel Immune‐Related Adverse Event of Combined Ipilimumab and Nivolumab Therapy for Renal Cell Carcinoma: A Case Report},
  journal = {IJU Case Reports},
  year = {2026},
  volume = {9},
  number = {4},
  doi = {10.1002/iju5.70207}
}
Kostenlos starten →